RadNet Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
RadNet s intäkter har minskat med en genomsnittlig årlig takt på -56.9%, medan Healthcare -branschen såg intäkter på växande 4% årligen. Intäkterna har varit växande med en genomsnittlig takt på 11.3% per år.
Viktig information
-56.94%
Tillväxttakt i vinsten
-57.77%
Tillväxttakt för EPS
| Healthcare Tillväxt i branschen | 8.50% |
| Intäkternas tillväxttakt | 11.32% |
| Avkastning på eget kapital | 1.63% |
| Nettomarginal | -0.66% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Analysartikel • May 14
Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report
Last week, you might have seen that RadNet, Inc. ( NASDAQ:RDNT ) released its quarterly result to the market. The early...
Uppdatering av berättelse • May 07
RDNT: Imaging Platform Execution And New Idaho Venture Will Support Future Earnings
Analysts have trimmed their fair value estimate for RadNet by $0.50 to $89.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E after recent Street research, including a lower $4 price target from B. Riley and an upgrade of Lumexa Imaging at Raymond James.Uppdatering av berättelse • Apr 23
RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility
Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.Uppdatering av berättelse • Apr 08
RDNT: Outpatient Imaging Shift Will Support Future Earnings Visibility
RadNet's analyst price target now stands at $92. Analysts cite outpatient diagnostic imaging growth drivers, Medicare reimbursement support, potential capital deployment, and an AI ramp as key reasons for maintaining this level.Uppdatering av berättelse • Mar 25
RDNT: Outpatient Imaging Shift And AI Adoption Will Drive Future Upside
Analysts kept their $92 price target for RadNet unchanged, citing what they see as attractive long term growth drivers in outpatient diagnostic imaging, reasonable 2025 to 2028 company targets, supportive Medicare reimbursement trends, potential capital deployment benefits, and expected AI contributions. Analyst Commentary Bullish Takeaways Bullish analysts view outpatient diagnostic imaging as an attractive subsector, with hospital to outpatient shifts and growing demand for advanced imaging seen as key growth drivers that support RadNet's long term story and current valuation framework.Uppdatering av berättelse • Mar 09
RDNT: Outpatient Imaging Shift And AI Ramp Will Support Future Upside
Analysts have raised their price target on RadNet from $91.75 to $92.38. The updated target reflects revised assumptions that incorporate higher projected revenue growth, a lower profit margin outlook, and a higher future P/E multiple supported by recent bullish Street research on outpatient imaging and AI benefits.Uppdatering av berättelse • Feb 22
RDNT: Outpatient Imaging Shift And AI Adoption Will Support Future Upside
Analysts have trimmed their implied future P/E assumption for RadNet, leading to a slightly lower blended price target of about $97 vs. roughly $102 previously.Uppdatering av berättelse • Feb 08
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Support Upside
Analysts have raised their price target on RadNet to about $92, reflecting confidence in the outpatient diagnostic imaging segment and the company's 2025 to 2028 targets, including expected benefits from improved Medicare rates, potential capital deployment, and increasing AI contributions. Analyst Commentary Recent research reflects a generally constructive tone on RadNet, with several firms lifting price targets into the high US$80s to low US$90s range and highlighting both the core imaging business and longer term AI potential.Uppdatering av berättelse • Jan 24
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Drive Upside
Analysts lifted their price target on RadNet to about US$91.75 from roughly US$91.71, reflecting recent coverage that highlights outpatient imaging growth drivers, supportive Medicare reimbursement, capital deployment options, and potential contributions from artificial intelligence (AI). Analyst Commentary Recent Street research on RadNet focuses on outpatient imaging growth, long term targets and the role of AI and capital allocation in supporting the current valuation framework.Uppdatering av berättelse • Jan 09
RDNT: Outpatient Imaging And AI Adoption Will Drive Future Outperformance
Analysts have raised their price target on RadNet to about US$92, citing what they view as reasonable 2025 to 2028 goals, supportive Medicare reimbursement trends, potential capital deployment upside, and growing contributions from AI and outpatient imaging demand. Analyst Commentary Recent research has focused on how RadNet's outpatient imaging footprint, AI initiatives, and long term financial targets could support its valuation and growth ambitions.Uppdatering av berättelse • Dec 13
RDNT: Integrated Offerings And Margin Expansion Will Drive Future Outperformance
Analysts have modestly increased their price target on RadNet, citing stronger long term growth and margin expansion prospects highlighted at the recent investor day and reflected in updated fair value estimates rising from about $91.71 to roughly $92.50 per share, alongside reaffirmed expectations for double digit revenue growth and mid teens EBITDA expansion. Analyst Commentary Bullish analysts highlight that the updated 2028 targets for double digit revenue growth and margin expansion underpin a durable mid teens EBITDA growth profile, which they view as supportive of further multiple expansion from current levels.Uppdatering av berättelse • Nov 28
RDNT: Sustained Demand And Integrated Offerings Will Drive Future Outperformance
Analysts have raised their price target for RadNet from approximately $87 to $93, citing higher revenue growth expectations and confidence in the company’s integrated offerings and sustained demand. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for RadNet, citing encouraging revenue growth expectations and confidence in the company’s ability to deliver sustained margin expansion.Analysartikel • Nov 14
Earnings Miss: RadNet, Inc. Missed EPS By 65% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that RadNet, Inc. ( NASDAQ:RDNT ) filed its third-quarter result this time last week...Uppdatering av berättelse • Nov 13
RDNT: Momentum Will Accelerate From Surging Demand And Integrated Offerings
RadNet’s analyst price target has increased from $80.57 to $86.67. This reflects confidence from analysts who cite strong demand, integrated offerings, and positive industry momentum as key drivers.Uppdatering av berättelse • Oct 30
RDNT: Imaging Center Demand And Digital Health Will Drive Measured Upside Potential
Analysts have increased their price target for RadNet from $74 to $81. They cite strong core imaging center demand and ongoing investments in digital health as key factors for the optimistic outlook.Uppdatering av berättelse • Oct 15
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet's analyst price target has been raised from $79.29 to $80.57 per share. This change reflects analysts' optimism amid strong imaging center demand, ongoing digital health investments, and potential M&A opportunities.Uppdatering av berättelse • Sep 19
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution. Analyst Commentary Robust core imaging center demand trends indicate sustained growth potential.Analysartikel • Sep 12
RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Uppdatering av berättelse • Sep 04
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43. Analyst Commentary Robust core imaging center demand trends highlighted in recent management meetings.Seeking Alpha • Aug 18
RadNet: Bloated Capital Base Not Pulling Its Economic Weight (Rating Downgrade)
Summary I am downgrading RDNT stock to hold due to excessive capital requirements, bloated acquisitions, and declining returns on invested capital despite strong top-line growth. The valuation is stretched, with RadNet trading at 78x EBIT and >5x book value, while debt levels and working capital intensity have surged. Operating margins are compressing, free cash flow yields have turned negative, and acquisitions are not delivering sufficient economic returns. I will reconsider a more bullish stance only if RDNT demonstrates margin expansion, improved capital productivity, or stronger free cash flow generation. Read the full article on Seeking AlphaAnalysartikel • Jul 31
Some Confidence Is Lacking In RadNet, Inc.'s (NASDAQ:RDNT) P/S
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Analysartikel • Jul 15
RadNet (NASDAQ:RDNT) May Have Issues Allocating Its Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysartikel • Jun 10
We Think RadNet (NASDAQ:RDNT) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • May 15
RadNet, Inc. (NASDAQ:RDNT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Investors in RadNet, Inc. ( NASDAQ:RDNT ) had a good week, as its shares rose 9.8% to close at US$60.34 following the...Analysartikel • May 07
Is There An Opportunity With RadNet, Inc.'s (NASDAQ:RDNT) 37% Undervaluation?
Key Insights The projected fair value for RadNet is US$84.18 based on 2 Stage Free Cash Flow to Equity Current share...Analysartikel • Apr 24
Is RadNet, Inc. (NASDAQ:RDNT) Potentially Undervalued?
RadNet, Inc. ( NASDAQ:RDNT ), might not be a large cap stock, but it received a lot of attention from a substantial...Analysartikel • Apr 11
Returns On Capital Signal Tricky Times Ahead For RadNet (NASDAQ:RDNT)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Seeking Alpha • Mar 11
RadNet: On The Sidelines For Now
Summary RDNT's stock performance has been lackluster, with only an 8.8% increase over the past year, currently trading at $50 per share. Despite decent fundamentals, including steady revenue growth and strong operating cash flow, RDNT faces risks from wage increases and weather-related disruptions. Recent market overreaction to temporary weather impacts presents a potential rebound opportunity, but the projected 8.6% return does not justify the investment risk. I rate RDNT as neutral due to uncertainties in revenue growth and bottom-line pressures, suggesting better opportunities elsewhere with more favorable risk-reward profiles. Read the full article on Seeking AlphaAnalysartikel • Feb 16
There's Reason For Concern Over RadNet, Inc.'s (NASDAQ:RDNT) Price
RadNet, Inc.'s ( NASDAQ:RDNT ) price-to-sales (or "P/S") ratio of 2.6x may not look like an appealing investment...Analysartikel • Jan 31
A Look At The Fair Value Of RadNet, Inc. (NASDAQ:RDNT)
Key Insights RadNet's estimated fair value is US$73.25 based on 2 Stage Free Cash Flow to Equity Current share price of...Analysartikel • Jan 16
Does RadNet (NASDAQ:RDNT) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Jan 01
Is It Time To Consider Buying RadNet, Inc. (NASDAQ:RDNT)?
RadNet, Inc. ( NASDAQ:RDNT ), might not be a large cap stock, but it received a lot of attention from a substantial...Analysartikel • Nov 12
There's Reason For Concern Over RadNet, Inc.'s (NASDAQ:RDNT) Massive 26% Price Jump
RadNet, Inc. ( NASDAQ:RDNT ) shares have continued their recent momentum with a 26% gain in the last month alone. The...Analysartikel • Oct 15
Here's What To Make Of RadNet's (NASDAQ:RDNT) Decelerating Rates Of Return
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Seeking Alpha • Oct 02
RadNet: Secular Tailwinds Underpinned By AI Monetization Prospects
Summary RadNet, the largest US diagnostic imaging operator, projects $1.8bn in 2024 revenue, driven by AI and Digital Health growth, and expanding imaging centers. Strong Q2 results with 13.9% revenue growth and 19.7% EBITDA increase, fueled by AI advancements and new imaging center openings. Future growth catalysts include market shifts to freestanding centers, increasing importance of joint ventures, and capital deployment for acquisitions and new facilities. Digital Health and AI initiatives, like DeepHealth OS and EBCD, are expected to drive significant revenue and margin expansion. Read the full article on Seeking AlphaAnalysartikel • Sep 22
Unpleasant Surprises Could Be In Store For RadNet, Inc.'s (NASDAQ:RDNT) Shares
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
Ny berättelse • Aug 30
Expanding Imaging Modalities And AI Integration Signal Strong Future Growth In Healthcare Sector
Expansion into advanced imaging and integration of AI technologies aim at boosting revenue through higher reimbursement rates and operational efficiencies.Seeking Alpha • Aug 24
RadNet: Growth In Operating Earnings Off Very Little Incremental Capital
Summary RDNT stock is up 10% since my June publication following a strong set of quarterly numbers in its Q2 FY'24 earnings. Management continue executing on the growth route, recycling funds into new store openings. Same-store procedure volumes continue to ratchet higher, evidencing increased utilization of its legacy base. Net-net, reiterate buy. Read the full article on Seeking AlphaAnalysartikel • Jul 22
RadNet (NASDAQ:RDNT) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Jun 05
Returns On Capital At RadNet (NASDAQ:RDNT) Have Stalled
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Seeking Alpha • Jun 05
RadNet: Qualified Growth Route, Still Undervalued
Summary RadNet, Inc. shares continue to show strength, having compounded by 184% since 2022. Q1 FY 2024 earnings showed growth in the Digital Health segment and increased MRI, CT, and PET/CT volumes. Management has increased its outlook on full-year revenues and projects $1.67-$1.7 billion in revenue for the year. Read the full article on Seeking AlphaAnalysartikel • May 10
Is There Now An Opportunity In RadNet, Inc. (NASDAQ:RDNT)?
While RadNet, Inc. ( NASDAQ:RDNT ) might not have the largest market cap around , it received a lot of attention from a...Analysartikel • Apr 08
Are RadNet, Inc. (NASDAQ:RDNT) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, RadNet fair value estimate is US$40.76 RadNet's US$49.04 share...Analysartikel • Mar 06
RadNet, Inc.'s (NASDAQ:RDNT) 26% Price Boost Is Out Of Tune With Revenues
The RadNet, Inc. ( NASDAQ:RDNT ) share price has done very well over the last month, posting an excellent gain of 26...Analysartikel • Feb 08
Why RadNet, Inc. (NASDAQ:RDNT) Could Be Worth Watching
RadNet, Inc. ( NASDAQ:RDNT ), might not be a large cap stock, but it received a lot of attention from a substantial...Seeking Alpha • Jan 28
RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation
Summary RadNet, Inc. is assessed as a Buy opportunity especially on price dips for retail value investors; watch its valuation and growth ratings. The company's share price has seen significant growth recently but may drop due to volatility and potential missed estimates. RadNet is at the forefront of the movement to bring diagnostic imaging services out of hospitals, offering lower costs and increased accessibility. Read the full article on Seeking AlphaAnalysartikel • Dec 28
Getting In Cheap On RadNet, Inc. (NASDAQ:RDNT) Might Be Difficult
There wouldn't be many who think RadNet, Inc.'s ( NASDAQ:RDNT ) price-to-sales (or "P/S") ratio of 1.5x is worth a...Analysartikel • Dec 04
We Think RadNet (NASDAQ:RDNT) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Aug 27
RadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital Effectively
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Analysartikel • Aug 09
RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Mar 30
We Think RadNet (NASDAQ:RDNT) Is Taking Some Risk With Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur RadNet tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 2,144 | -14 | 116 | 0 |
| 31 Dec 25 | 2,040 | -19 | 116 | 0 |
| 30 Sep 25 | 1,970 | -13 | 110 | 0 |
| 30 Jun 25 | 1,908 | -15 | 110 | 0 |
| 31 Mar 25 | 1,869 | -32 | 110 | 0 |
| 31 Dec 24 | 1,830 | 3 | 110 | 0 |
| 30 Sep 24 | 1,773 | -4 | 16 | 0 |
| 30 Jun 24 | 1,714 | 10 | 45 | 0 |
| 31 Mar 24 | 1,658 | 21 | 75 | 0 |
| 31 Dec 23 | 1,617 | 3 | 104 | 0 |
| 30 Sep 23 | 1,580 | 4 | 140 | 0 |
| 30 Jun 23 | 1,528 | -13 | 142 | 0 |
| 31 Mar 23 | 1,479 | -13 | 143 | 0 |
| 31 Dec 22 | 1,430 | 11 | 107 | 0 |
| 30 Sep 22 | 1,382 | 8 | 1 | 0 |
| 30 Jun 22 | 1,365 | 23 | 1 | 0 |
| 31 Mar 22 | 1,344 | 18 | 1 | 0 |
| 31 Dec 21 | 1,324 | 25 | 0 | 0 |
| 30 Sep 21 | 1,297 | 35 | 199 | 0 |
| 30 Jun 21 | 1,256 | 24 | 115 | 0 |
| 31 Mar 21 | 1,138 | 11 | 110 | 0 |
| 31 Dec 20 | 1,098 | -15 | 0 | 0 |
| 30 Sep 20 | 1,090 | -10 | 106 | 0 |
| 30 Jun 20 | 1,091 | -13 | 108 | 0 |
| 31 Mar 20 | 1,164 | 2 | 133 | 0 |
| 31 Dec 19 | 1,154 | 15 | 0 | 0 |
| 30 Sep 19 | 1,111 | 33 | 24 | 0 |
| 30 Jun 19 | 1,060 | 35 | 99 | 0 |
| 31 Mar 19 | 1,015 | 36 | 90 | 0 |
| 31 Dec 18 | 975 | 32 | 0 | 0 |
| 30 Sep 18 | 953 | -4 | 85 | 0 |
| 30 Jun 18 | 939 | -6 | 83 | 0 |
| 31 Mar 18 | 925 | -6 | 59 | 0 |
| 31 Dec 17 | 922 | 0 | 0 | 0 |
| 30 Sep 17 | 912 | 11 | 77 | 0 |
| 30 Jun 17 | 909 | 9 | 74 | 0 |
| 31 Mar 17 | 897 | 7 | 75 | 0 |
| 31 Dec 16 | 885 | 7 | 74 | 0 |
| 30 Sep 16 | 875 | 5 | 75 | 0 |
| 30 Jun 16 | 859 | 11 | 76 | 0 |
| 31 Mar 16 | 845 | 11 | 74 | 0 |
| 31 Dec 15 | 810 | 8 | 72 | 0 |
| 30 Sep 15 | 779 | 11 | 70 | 0 |
| 30 Jun 15 | 755 | 7 | 68 | 0 |
Kvalitetsintäkter: RDNT är för närvarande olönsam.
Växande vinstmarginal: RDNT är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: RDNT är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 56.9% per år.
Accelererande tillväxt: Det går inte att jämföra RDNT s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: RDNT är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Healthcare branschen ( 17% ).
Avkastning på eget kapital
Hög ROE: RDNT har en negativ avkastning på eget kapital ( 1.63% ), eftersom det för närvarande är olönsamt.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 20:42 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
RadNet, Inc. bevakas av 12 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Sarah James | Barclays |
| Andrew Mok | Barclays |
| Yuan Zhi | B. Riley Securities, Inc. |